Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Enzymatica AB is a biotechnology company that develops medical device products utilizing its proprietary enzyme technology. The company's primary function is to create healthcare products aimed at preventing, treating, and alleviating viral infections and inflammatory conditions. Enzymatica's products typically harness cold-adapted enzymes to enhance their efficacy in various healthcare solutions, particularly within the respiratory health segment. One of its notable products is ColdZyme, a mouth spray designed to protect against the common cold by forming a protective barrier on the mucous membrane of the throat. Operating primarily in the pharmaceutical and biotechnology sectors, Enzymatica AB plays a crucial role in innovating non-prescription therapeutic solutions that offer preventative care and symptom relief. The company maintains its market significance by addressing prevalent health issues and leveraging biotechnological advances to offer consumers effective healthcare products. Headquartered in Sweden, Enzymatica's reach extends globally, allowing it to impact health and wellness on an international scale through strategic partnerships and distribution networks.
kr 0.19
kr 0.00 (-2.01%)
EOD Jun 23, 2026 · Twelve Data
The business is unprofitable at the operating level (-95.30% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 18.3% YoY with margins expanding 18.9pp.
Negative free cash flow of -kr 41M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 53M
▲ +18.3% YoY
Net Income (TTM)
-kr 47M
▲ +2.4% YoY
Op. Margin
-88.47%
▲ +18.9pp YoY
ROIC
-26.72%
▲ +3.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 39M
▲ +32.3% YoY
Op. Cash Flow (TTM)
-kr 39M
▲ +32.3% YoY
Net Debt
-kr 32M
Net Cash Position
Cash & Equiv.
kr 33M
3Y CAGR: +3.3%
Continue Research
Enzymatica AB (ENZY.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Enzymatica AB scores 33/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Enzymatica AB scores 33 out of 100 on Intrinsiqq's quality score, passing 2 of 6 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -88.5% operating margin and a -26.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ENZY.XSTO's valuation and scores 33/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.